Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZGNX

Zogenix (ZGNX) Stock Price, News & Analysis

Zogenix logo

About Zogenix Stock (NASDAQ:ZGNX)

Advanced Chart

Key Stats

Today's Range
$26.68
$26.68
50-Day Range
$26.10
$26.68
52-Week Range
$11.03
$26.90
Volume
94 shs
Average Volume
3.76 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Stock News Headlines

Hwasung Industrial Co Ltd 002460
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A
Biocryst Pharmaceuticals
See More Headlines

ZGNX Stock Analysis - Frequently Asked Questions

Zogenix, Inc. (NASDAQ:ZGNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The firm's revenue for the quarter was up 690.6% compared to the same quarter last year.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol-Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/04/2021
Today
6/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ZGNX
Employees
218
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$209.38 million
Net Margins
-278.38%
Pretax Margin
-278.26%

Debt

Sales & Book Value

Annual Sales
$81.69 million
Price / Cash Flow
N/A
Book Value
$6.64 per share
Price / Book
4.02

Miscellaneous

Free Float
53,922,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.89
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ZGNX) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners